Brokers Set Expectations for Neurogene Inc.’s Q1 2025 Earnings (NASDAQ:NGNE)

Neurogene Inc. (NASDAQ:NGNE) – Investment analysts at William Blair issued their Q1 2025 EPS estimates for shares of Neurogene in a report issued on Tuesday, May 7th. William Blair analyst S. Corwin anticipates that the company will post earnings of ($0.84) per share for the quarter. William Blair has a “Outperform” rating and a $61.00 price target on the stock. The consensus estimate for Neurogene’s current full-year earnings is ($3.98) per share. William Blair also issued estimates for Neurogene’s Q2 2025 earnings at ($0.82) EPS, Q3 2025 earnings at ($0.78) EPS and Q4 2025 earnings at ($0.79) EPS.

Several other equities research analysts have also recently commented on the stock. SVB Leerink assumed coverage on shares of Neurogene in a research report on Monday, April 29th. They set an “outperform” rating and a $46.00 price target on the stock. Leerink Partnrs reaffirmed an “outperform” rating on shares of Neurogene in a report on Monday, April 29th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $55.00 target price on shares of Neurogene in a report on Friday, May 3rd. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of “Buy” and an average target price of $48.25.

Neurogene Stock Down 3.1 %

Shares of NASDAQ:NGNE opened at $32.90 on Thursday. The business’s 50-day simple moving average is $38.39. Neurogene has a one year low of $12.20 and a one year high of $53.00. The company has a market cap of $423.42 million, a PE ratio of -2.64 and a beta of 1.36.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. BML Capital Management LLC acquired a new position in Neurogene in the 4th quarter valued at about $478,000. SG Americas Securities LLC acquired a new position in Neurogene in the 1st quarter valued at about $120,000. Privium Fund Management UK Ltd acquired a new position in Neurogene in the 1st quarter valued at about $274,000. Great Point Partners LLC acquired a new position in Neurogene in the 4th quarter valued at about $19,268,000. Finally, Avidity Partners Management LP acquired a new position in Neurogene in the 4th quarter valued at about $9,036,000. Institutional investors and hedge funds own 52.37% of the company’s stock.

About Neurogene

Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.